A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.

Tyler RobinsonJune Escara-WilkeJinlu DaiJohann ZimmermannEvan T Keller

Published in: The Prostate (2023)

Our data demonstrate that a combination of BAL and DOC has greater antitumor activity in a model of PCa bone metastases than either drug alone. These data support further evaluation of this combination in metastatic PCa.

Keyphrases

prostate cancer
electronic health record
big data
squamous cell carcinoma
small cell lung cancer
radical prostatectomy
emergency department
locally advanced
radiation therapy
soft tissue
rectal cancer
postmenopausal women